A Comparison of Sevelamer and Calcium-Based Phosphate.
Phosphate-binder therapy for hyperphosphataemia is key to the treatment of patients with chronic kidney disease (CKD)-mineral and bone disorder (MBD). Calcium-free phosphate binders are increasingly favoured since calcium-based agents potentially cause harmful calcium overload and vascular calcification that confound the benefits of reducing serum phosphorus.
Phosphate binders are used to decrease the absorption of phosphate from food in the digestive tract. They are used when there is an abnormally high blood phosphate level ( hyperphosphatemia ) which can be caused by impaired renal phosphate excretion or increased extracellular fluid phosphate loads.
Phosphate binders (calcium-based and calcium-free) are recommended to lower serum phosphate and prevent hyperphosphataemia in patients with chronic kidney disease, but their effects on mortality and cardiovascular outcomes are unknown.
A Comparison of Sevelamer and Calcium-Based Phosphate Binders on Mortality, Hospitalization, and Morbidity in Hemodialysis: A Secondary Analysis of the Dialysis Clinical Outcomes Revisited (DCOR) Randomized Trial Using Claims Data Wendy L. St. Peter, PharmD,1,2 Jiannong Liu, PhD, 1Eric Weinhandl, MS, and Qiao Fan, MS1.
Phosphate Binders (Non-Calcium, Non-Aluminum) Lanthanum Carbonate, Sevelamer Carbonate, Ferric Citrate, Sucroferric Oxyhydroxide For the Management of Hyperphosphatemia in Chronic Kidney Disease Recommendations for Use May 2016.
A recent meta-analysis of phosphate binders reported that no phosphate binder reduced mortality compared to placebo in adults with chronic kidney disease. 56 More importantly, sevelamer resulted in lower mortality than calcium-based drugs, while the comparative effects of lanthanum, iron-based drugs and colestilan were less certain. 56.
Calcium-based phosphate binders and chronic kidney disease We have concerns regarding Sophie Jamal and colleagues’ Article (Oct 12, p 1268)1 on the effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease.
A Comparison of Sevelamer and Calcium-Based Phosphate Binders on Mortality, Hospitalization, and Morbidity in Hemodialysis: A Secondary Analysis of the Dialysis Clinical Outcomes Revisited (DCOR) Randomized Trial Using Claims Data.
New Conclusions Regarding Comparison of Sevelamer and Calcium-Based Phosphate Binders in Coronary-Artery Calcification for Dialysis Patients: A Meta-Analysis of Randomized Controlled Trials. Caixia Wang, Xun Liu, Yongming Zhou, Shaomin Li, Yanbing Chen, Yanni Wang, Tanqi Lou.
In The Lancet, Sophie Jamal and colleagues1 report an updated systematic review and meta-analysis of the effect on mortality of treatment of chronic kidney disease hyperphosphataemia with calcium-based versus non-calcium-based phosphate binders. Kidneys excrete excess dietary phosphate, therefore loss of renal function leads to a positive phosphate balance that ultimately results in.
If calcium is already being used as a supplement, additional calcium used as a phosphate binder may cause hypercalcemia and tissue-damaging calcinosis. One may avoid these adverse effects by using phosphate binders that do not contain calcium or aluminium as active ingredient s, such as lanthanum carbonate or sevelamer.
Use of phosphate binders is recommended for lowering serum phosphate level and treating hyperphosphataemia in patients with chronic kidney disease (CKD); however, the benefit of non-calcium-based.
A Comparison of Sevelamer and Calcium-Based Phosphate Binders on Mortality, Hospitalization, and Morbidity in Hemodialysis: A Secondary Analysis of the Dialysis Clinical Outcomes Revisited (DCOR.
